T315I – a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia
Sub-optimal response or failure to TKI treatment indicates the development of resistance due to the presence of T315I mutation or other mutation(s). Early identification will help redirect the patient's treatment.
Authors
- Bushra Kaleem (ORCID: https://orcid.org/0000-0003-3153-0672)
- Sadaf Shahab (ORCID: https://orcid.org/0000-0002-0810-6649)
- Tahir Shamsi (ORCID: https://orcid.org/0000-0001-7667-5838)
Institutions
- National Institute Of Blood Disease and Bone Marrow Transplantation (PK)
Publication Details
- Journal
- Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1515/almed-2024-0069
- Citations
- 4
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.82